We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Genetic Tests to Speed Diagnosis of Lymphatic Disorders

By LabMedica International staff writers
Posted on 23 Feb 2026

Defects in the lymphatic system affect approximately one in every 3,500 newborns and can lead to severe complications, including organ failure, breathing difficulties, and life-threatening infections. More...

However, many patients wait years for an accurate diagnosis because lymphatic disorders are often misidentified or lack known genetic causes. Now, a collaborative initiative aims to accelerate diagnosis by developing comprehensive genetic tests for congenital lymphatic diseases.

The initiative, known as CLARUM (Comprehensive Lymphatic Anomaly Revealing and Understanding Genomics), is led by Columbia University Vagelos College of Physicians and Surgeons (New York, NY, USA) and supported by a two-year USD 8.7 million contract from the Advanced Research Projects Agency for Health (ARPA-H) through its LIGHT program. The goal is to identify new genetic mutations responsible for lymphatic anomalies and develop two clinical genetic panels capable of screening for germline and mosaic mutations across 73 known genes associated with primary lymphatic diseases.

CLARUM will analyze genetic data from 2,000 patients across multiple centers to discover at least 15 new causative mutations. The team will apply advanced bioinformatics tools to identify novel genes, while also using cell-based and zebrafish models to assess variants of uncertain significance. The project also aims to develop methods to detect mosaic mutations before birth, potentially preventing ineffective or harmful treatments in fetuses with cystic lymphatic malformations.

By shortening the time to genetic diagnosis from years to weeks, the project could enable faster access to FDA-approved targeted therapies. Currently, only 20% to 30% of patients with identified mutations benefit from mutation-specific treatments. Expanding the number of known genetic causes may significantly broaden treatment eligibility. By working with technology ventures programs, the team aims to commercialize the genetic panels for use across the US, increasing access beyond major urban medical centers.

“Discovering genes that cause lymphatic anomalies and using this information to create new clinical tests will not only accelerate the diagnosis of patients, but will also lead to improved treatments and, most importantly, save lives,” said associate professor Carrie Shawber, PhD, principal investigator of the CLARUM project.

Related Links:
Vagelos College of Physicians and Surgeons 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
Hematology Consumables
Bioblood Devices
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image Credit: Adobe Stock

Mayo Clinic and Thermo Fisher Launch Multi-Omics Venture to Identify Early Disease Signals

Many diseases begin developing years before symptoms emerge, making early detection difficult for healthcare systems and clinical laboratories. Linking molecular changes with longitudinal health data could... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.